Letters

Advertisement for Zantac

BMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6953.540 (Published 20 August 1994) Cite this as: BMJ 1994;309:540
  1. F M Hickey
  1. Grampian Health Board, Aberdeen AB9 1RE
  2. Glaxo Laboratories, Uxbridge, Middlesex UB11 1BT.

    EDITOR, - I am concerned by the advertisement for Zantac that has appeared in the BMJ.1 It reads: “It's an effective treatment. Successfully healing both duodental and gastric ulcers. But, used as prophylaxis, Zantac can actually prevent NSAID-associated duodenal ulcers. In fact it's the only H2 licensed to do this.”

    The most likely site of any damage to the gastrointestinal tract associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is the gastric mucosa and not the duodenum.2 The British National Formulary states, “Therapy [with H2 antagonists] can promote the healing of NSAID-associated ulcers but there is no proof that the ulcer complications are prevented.”3 Zantac is licensed for prophylaxis against …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe